Abstract
Cholangiocarcinoma (CCA) is the second most common primary malignancy of the liver arising from malignant transformation and growth of biliary ductal epithelium. Approximately 50–70 % of CCAs arise at the hilar plate of the biliary tree, which are termed hilar cholangiocarcinoma (HC). Various staging systems are currently employed to classify HCs and determine resectability. Depending on the pre-operative staging, the mainstays of treatment include surgery, chemotherapy, radiation therapy, and photodynamic therapy. Surgical resection offers the only chance for cure of HC and achieving an R0 resection has demonstrated improved overall survival. However, obtaining longitudinal and radial surgical margins that are free of tumor can be difficult and frequently requires extensive resections, particularly for advanced HCs. Pre-operative interventions may be necessary to prepare patients for major hepatic resections, including endoscopic retrograde cholangiopancreatography, percutaneous transhepatic cholangiography, and portal vein embolization. Multimodal therapy that combines chemotherapy with external beam radiation, stereotactic body radiation therapy, bile duct brachytherapy, and/or photodynamic therapy are all possible strategies for advanced HC prior to resection. Orthotopic liver transplantation is another therapeutic option that can achieve complete extirpation of locally advanced HC in judiciously selected patients following standardized neoadjuvant protocols.
Similar content being viewed by others
References
Altemeier WA, Gall EA, Zinninger MM, Hoxworth PI (1957) Sclerosing carcinoma of the major intrahepatic bile ducts. AMA Arch Surg 75(3):450–460, discussion 60–1
Klatskin G (1965) Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. an unusual tumor with distinctive clinical and pathological features. Am J Med 38:241–256
Ramia JM (2013) Hilar cholangiocarcinoma. World J Gastrointest Oncol 5(7):113–114
Suarez-Munoz MA, Fernandez-Aguilar JL, Sanchez-Perez B, Perez-Daga JA, Garcia-Albiach B, Pulido-Roa Y et al (2013) Risk factors and classifications of hilar cholangiocarcinoma. World J Gastrointest Oncol 5(7):132–138
Welzel TM, McGlynn KA, Hsing AW, O’Brien TR, Pfeiffer RM (2006) Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 98(12):873–875
Choi JY, Kim MJ, Lee JM, Kim KW, Lee JY, Han JK et al (2008) Hilar cholangiocarcinoma: role of preoperative imaging with sonography, MDCT, MRI, and direct cholangiography. AJR Am J Roentgenol 191(5):1448–1457
Ruys AT, van Beem BE, Engelbrecht MR, Bipat S, Stoker J, Van Gulik TM (2012) Radiological staging in patients with hilar cholangiocarcinoma: a systematic review and meta-analysis. Br J Radiol 85(1017):1255–1262
Cho MS, Kim SH, Park SW, Lim JH, Choi GH, Park JS et al (2012) Surgical outcomes and predicting factors of curative resection in patients with hilar cholangiocarcinoma: 10-year single-institution experience. J Gastrointest Surg 16(9):1672–1679
Nuzzo G, Giuliante F, Ardito F, Giovannini I, Aldrighetti L, Belli G et al (2012) Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients. Arch Surg 147(1):26–34
Kobayashi A, Miwa S, Nakata T, Miyagawa S (2010) Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg 97(1):56–64
Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, DeMatteo RP et al (2003) Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer 98(8):1689–1700
Cannon RM, Brock G, Buell JF (2012) Surgical resection for hilar cholangiocarcinoma: experience improves resectability. HPB 14(2):142–149
Saxena A, Chua TC, Chu FC, Morris DL (2011) Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg 202(3):310–320
Are C, Gonen M, D’Angelica M, DeMatteo RP, Fong Y, Blumgart LH et al (2006) Differential diagnosis of proximal biliary obstruction. Surgery 140(5):756–763
Corvera CU, Blumgart LH, Darvishian F, Klimstra DS, DeMatteo R, Fong Y et al (2005) Clinical and pathologic features of proximal biliary strictures masquerading as hilar cholangiocarcinoma. J Am Coll Surg 201(6):862–869
Gerhards MF, Vos P, van Gulik TM, Rauws EA, Bosma A, Gouma DJ (2001) Incidence of benign lesions in patients resected for suspicious hilar obstruction. Br J Surg 88(1):48–51
Welzel TM, Graubard BI, El-Serag HB, Shaib YH, Hsing AW, Davila JA et al (2007) Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case–control study. Clin Gastroenterol Hepatol 5(10):1221–1228
Choi D, Lim JH, Lee KT, Lee JK, Choi SH, Heo JS et al (2006) Cholangiocarcinoma and Clonorchis sinensis infection: a case–control study in Korea. J Hepatol 44(6):1066–1073
Parkin DM, Srivatanakul P, Khlat M, Chenvidhya D, Chotiwan P, Insiripong S et al (1991) Liver cancer in Thailand. I. A case–control study of cholangiocarcinoma. Int J Cancer 48(3):323–328
Patel AH, Harnois DM, Klee GG, LaRusso NF, Gores GJ (2000) The utility of CA 19–9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 95(1):204–207
Juntermanns B, Radunz S, Heuer M, Hertel S, Reis H, Neuhaus JP et al (2010) Tumor markers as a diagnostic key for hilar cholangiocarcinoma. Eur J Med Res 15(8):357–361
Park MS, Kim TK, Kim KW, Park SW, Lee JK, Kim JS et al (2004) Differentiation of extrahepatic bile duct cholangiocarcinoma from benign stricture: findings at MRCP versus ERCP. Radiology 233(1):234–240
Silva MA, Tekin K, Aytekin F, Bramhall SR, Buckels JA, Mirza DF (2005) Surgery for hilar cholangiocarcinoma; a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 31(5):533–539
Ponchon T, Gagnon P, Berger F, Labadie M, Liaras A, Chavaillon A et al (1995) Value of endobiliary brush cytology and biopsies for the diagnosis of malignant bile duct stenosis: results of a prospective study. Gastrointest Endosc 42(6):565–572
Sugiyama M, Atomi Y, Wada N, Kuroda A, Muto T (1996) Endoscopic transpapillary bile duct biopsy without sphincterotomy for diagnosing biliary strictures: a prospective comparative study with bile and brush cytology. Am J Gastroenterol 91(3):465–467
Kubota Y, Takaoka M, Tani K, Ogura M, Kin H, Fujimura K et al (1993) Endoscopic transpapillary biopsy for diagnosis of patients with pancreaticobiliary ductal strictures. Am J Gastroenterol 88(10):1700–1704
Tamada K, Tomiyama T, Wada S, Ohashi A, Satoh Y, Ido K et al (2002) Endoscopic transpapillary bile duct biopsy with the combination of intraductal ultrasonography in the diagnosis of biliary strictures. Gut 50(3):326–331
Domagk D, Poremba C, Dietl KH, Senninger N, Heinecke A, Domschke W et al (2002) Endoscopic transpapillary biopsies and intraductal ultrasonography in the diagnostics of bile duct strictures: a prospective study. Gut 51(2):240–244
Farrell RJ, Agarwal B, Brandwein SL, Underhill J, Chuttani R, Pleskow DK (2002) Intraductal US is a useful adjunct to ERCP for distinguishing malignant from benign biliary strictures. Gastrointest Endosc 56(5):681–687
Lee JH, Salem R, Aslanian H, Chacho M, Topazian M (2004) Endoscopic ultrasound and fine-needle aspiration of unexplained bile duct strictures. Am J Gastroenterol 99(6):1069–1073
Eloubeidi MA, Chen VK, Jhala NC, Eltoum IE, Jhala D, Chhieng DC et al (2004) Endoscopic ultrasound-guided fine needle aspiration biopsy of suspected cholangiocarcinoma. Clin Gastroenterol Hepatol 2(3):209–213
Byrne MF, Gerke H, Mitchell RM, Stiffler HL, McGrath K, Branch MS et al (2004) Yield of endoscopic ultrasound-guided fine-needle aspiration of bile duct lesions. Endoscopy 36(8):715–719
Heimbach JK, Sanchez W, Rosen CB, Gores GJ (2011) Trans-peritoneal fine needle aspiration biopsy of hilar cholangiocarcinoma is associated with disease dissemination. HPB 13(5):356–360
Choi ER, Chung YH, Lee JK, Lee KT, Lee KH, Choi DW et al (2011) Preoperative evaluation of the longitudinal extent of borderline resectable hilar cholangiocarcinoma by intraductal ultrasonography. J Gastroenterol Hepatol 26(12):1804–1810
Watadani T, Akahane M, Yoshikawa T, Ohtomo K (2008) Preoperative assessment of hilar cholangiocarcinoma using multidetector-row CT: correlation with histopathological findings. Radiat Med 26(7):402–407
Aloia TA, Charnsangavej C, Faria S, Ribero D, Abdalla EK, Vauthey JN et al (2007) High-resolution computed tomography accurately predicts resectability in hilar cholangiocarcinoma. Am J Surg 193(6):702–706
Cha JH, Han JK, Kim TK, Kim AY, Park SJ, Choi BI et al (2000) Preoperative evaluation of Klatskin tumor: accuracy of spiral CT in determining vascular invasion as a sign of unresectability. Abdom Imaging 25(5):500–507
Chen HW, Lai EC, Pan AZ, Chen T, Liao S, Lau WY (2009) Preoperative assessment and staging of hilar cholangiocarcinoma with 16-multidetector computed tomography cholangiography and angiography. Hepato-Gastroenterology 56(91–92):578–583
Sai JK, Suyama M, Kubokawa Y, Watanabe S, Maehara T (2009) Early detection of extrahepatic bile-duct carcinomas in the nonicteric stage by using MRCP followed by EUS. Gastrointest Endosc 70(1):29–36
Cherqui D, Benoist S, Malassagne B, Humeres R, Rodriguez V, Fagniez PL (2000) Major liver resection for carcinoma in jaundiced patients without preoperative biliary drainage. Arch Surg 135(3):302–308
Farges O, Regimbeau JM, Fuks D, Le Treut YP, Cherqui D, Bachellier P et al (2013) Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma. Br J Surg 100(2):274–283
Grandadam S, Compagnon P, Arnaud A, Olivie D, Malledant Y, Meunier B et al (2010) Role of preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma type III. Ann Surg Oncol 17(12):3155–3161
Tsai HM, Chuang CH, Lin XZ, Chen CY (2009) Factors relating to the short term effectiveness of percutaneous biliary drainage for hilar cholangiocarcinoma. World J Gastroenterol 15(41):5206–5210
Young AL, Igami T, Senda Y, Adair R, Farid S, Toogood GJ et al (2011) Evolution of the surgical management of perihilar cholangiocarcinoma in a Western centre demonstrates improved survival with endoscopic biliary drainage and reduced use of blood transfusion. HPB 13(7):483–493
Belghiti J, Ogata S (2005) Preoperative optimization of the liver for resection in patients with hilar cholangiocarcinoma. HPB 7(4):252–253
Lai EC, Chu KM, Lo CY, Mok FP, Fan ST, Lo CM et al (1992) Surgery for malignant obstructive jaundice: analysis of mortality. Surgery 112(5):891–896
Clements WD, Diamond T, McCrory DC, Rowlands BJ (1993) Biliary drainage in obstructive jaundice: experimental and clinical aspects. Br J Surg 80(7):834–842
Makino H, Shimizu H, Ito H, Kimura F, Ambiru S, Togawa A et al (2006) Changes in growth factor and cytokine expression in biliary obstructed rat liver and their relationship with delayed liver regeneration after partial hepatectomy. World J Gastroenterol 12(13):2053–2059
Yamano T, Hirai R, Hato S, Uemura T, Shimizu N (2002) Delayed liver regeneration with negative regulation of hepatocyte growth factor and positive regulation of transforming growth factor-beta1 mRNA after portal branch ligation in biliary obstructed rats. Surgery 131(2):163–171
Kennedy TJ, Yopp A, Qin Y, Zhao B, Guo P, Liu F et al (2009) Role of preoperative biliary drainage of liver remnant prior to extended liver resection for hilar cholangiocarcinoma. HPB 11(5):445–451
Yokoyama Y, Nagino M, Nishio H, Ebata T, Igami T, Nimura Y (2007) Recent advances in the treatment of hilar cholangiocarcinoma: portal vein embolization. J Hepato-Biliary-Pancreat Surg 14(5):447–454
Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V et al (2003) Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 237(2):208–217
Abdalla EK, Barnett CC, Doherty D, Curley SA, Vauthey JN (2002) Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg 137(6):675–680, discussion 80–1
Makuuchi M, Thai BL, Takayasu K, Takayama T, Kosuge T, Gunven P et al (1990) Preoperative portal embolization to increase safety of major hepatectomy for hilar bile duct carcinoma: a preliminary report. Surgery 107(5):521–527
Hemming AW, Reed AI, Howard RJ, Fujita S, Hochwald SN, Caridi JG et al (2003) Preoperative portal vein embolization for extended hepatectomy. Ann Surg 237(5):686–691, discussion 91–3
van Lienden KP, van den Esschert JW, de Graaf W, Bipat S, Lameris JS, van Gulik TM et al (2013) Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol 36(1):25–34
Yi B, Xu AM, Lai EC, Qu ZQ, Cheng QB, Liu C et al (2010) Preoperative portal vein embolization for hilar cholangiocarcinoma—a comparative study. Hepato-Gastroenterology 57(104):1341–1346
Nagino M, Kamiya J, Nishio H, Ebata T, Arai T, Nimura Y (2006) Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 243(3):364–372
Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN (2007) Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 94(11):1386–1394
Bismuth H, Nakache R, Diamond T (1992) Management strategies in resection for hilar cholangiocarcinoma. Ann Surg 215(1):31–38
Paul A, Kaiser GM, Molmenti EP, Schroeder T, Vernadakis S, Oezcelik A et al (2011) Klatskin tumors and the accuracy of the Bismuth-Corlette classification. Am Surg 77(12):1695–1699
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BJ et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234(4):507–517, discussion 17–9
Matsuo K, Rocha FG, Ito K, D’Angelica MI, Allen PJ, Fong Y et al (2012) The Blumgart preoperative staging system for hilar cholangiocarcinoma: analysis of resectability and outcomes in 380 patients. J Am Coll Surg 215(3):343–355
Burke EC, Jarnagin WR, Hochwald SN, Pisters PW, Fong Y, Blumgart LH (1998) Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system. Ann Surg 228(3):385–394
Deoliveira ML, Schulick RD, Nimura Y, Rosen C, Gores G, Neuhaus P et al (2011) New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 53(4):1363–1371
Parikh AA, Abdalla EK, Vauthey JN (2005) Operative considerations in resection of hilar cholangiocarcinoma. HPB 7(4):254–258
Ruys AT, Busch OR, Gouma DJ, van Gulik TM (2012) Staging laparoscopy for hilar cholangiocarcinoma: is it still worthwhile? Indian J Surg Oncol 3(2):147–153
Connor S, Barron E, Wigmore SJ, Madhavan KK, Parks RW, Garden OJ (2005) The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg 9(4):476–480
Weber SM, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR (2002) Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 235(3):392–399
Barlow AD, Garcea G, Berry DP, Rajesh A, Patel R, Metcalfe MS et al (2013) Staging laparoscopy for hilar cholangiocarcinoma in 100 patients. Langenbecks Arch Surg/Deutsche Gesellschaft fur Chirurgie 398(7):983–988
Zheng-Rong L, Hai-Bo Y, Xin C, Chuan-Xin W, Zuo-Jin L, Bing T et al (2011) Resection and drainage of hilar cholangiocarcinoma: an 11-year experience of a single center in mainland China. Am Surg 77(5):627–633
Schiffman SC, Reuter NP, McMasters KM, Scoggins CR, Martin RC (2012) Overall survival peri-hilar cholangiocarcinoma: R1 resection with curative intent compared to primary endoscopic therapy. J Surg Oncol 105(1):91–96
Rocha FG, Matsuo K, Blumgart LH, Jarnagin WR (2010) Hilar cholangiocarcinoma: the Memorial Sloan-Kettering Cancer Center experience. J Hepato-Biliary-Pancreat Sci 17(4):490–496
Miyazaki M, Ito H, Nakagawa K, Ambiru S, Shimizu H, Shimizu Y et al (1998) Aggressive surgical approaches to hilar cholangiocarcinoma: hepatic or local resection? Surgery 123(2):131–136
de Jong MC, Marques H, Clary BM, Bauer TW, Marsh JW, Ribero D et al (2012) The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases. Cancer 118(19):4737–4747
Ikeyama T, Nagino M, Oda K, Ebata T, Nishio H, Nimura Y (2007) Surgical approach to Bismuth type I and II hilar cholangiocarcinomas: audit of 54 consecutive cases. Ann Surg 246(6):1052–1057
Neuhaus P, Jonas S, Settmacher U, Thelen A, Benckert C, Lopez-Hanninen E et al (2003) Surgical management of proximal bile duct cancer: extended right lobe resection increases resectability and radicality. Langenbecks Arch Surg/Deutsche Gesellschaft fur Chirurgie 388(3):194–200
Capussotti L, Vigano L, Ferrero A, Muratore A (2008) Local surgical resection of hilar cholangiocarcinoma: is there still a place? HPB 10(3):174–178
DeOliveira ML, Cunningham SC, Cameron JL, Kamangar F, Winter JM, Lillemoe KD et al (2007) Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 245(5):755–762
Ito F, Agni R, Rettammel RJ, Been MJ, Cho CS, Mahvi DM et al (2008) Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence. Ann Surg 248(2):273–279
Shi Z, Yang MZ, He QL, Ou RW, Chen YT (2009) Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma. World J Gastroenterol 15(15):1892–1896
Cheng QB, Yi B, Wang JH, Jiang XQ, Luo XJ, Liu C et al (2012) Resection with total caudate lobectomy confers survival benefit in hilar cholangiocarcinoma of Bismuth type III and IV. Eur J Surg Oncol 38(12):1197–1203
Kow AW, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ et al (2012) Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg 36(5):1112–1121
Dinant S, Gerhards MF, Busch OR, Obertop H, Gouma DJ, Van Gulik TM (2005) The importance of complete excision of the caudate lobe in resection of hilar cholangiocarcinoma. HPB 7(4):263–267
Regimbeau JM, Fuks D, Le Treut YP, Bachellier P, Belghiti J, Boudjema K et al (2011) Surgery for hilar cholangiocarcinoma: a multi-institutional update on practice and outcome by the AFC-HC study group. J Gastrointest Surg 15(3):480–488
Miyazaki M, Kimura F, Shimizu H, Yoshidome H, Otuka M, Kato A et al (2010) One hundred seven consecutive surgical resections for hilar cholangiocarcinoma of Bismuth types II, III, IV between 2001 and 2008. J Hepato-Biliary-Pancreat Sci 17(4):470–475
Wu XS, Dong P, Gu J, Li ML, Wu WG, Lu JH et al (2013) Combined portal vein resection for hilar cholangiocarcinoma: a meta-analysis of comparative studies. J Gastrointest Surg 17(6):1107–1115
Hemming AW, Mekeel K, Khanna A, Baquerizo A, Kim RD (2011) Portal vein resection in management of hilar cholangiocarcinoma. J Am Coll Surg 212(4):604–613, discussion 13–6
Miyazaki M, Kato A, Ito H, Kimura F, Shimizu H, Ohtsuka M et al (2007) Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery 141(5):581–588
Abbas S, Sandroussi C (2013) Systematic review and meta-analysis of the role of vascular resection in the treatment of hilar cholangiocarcinoma. HPB 15(7):492–503
Neuhaus P, Jonas S, Bechstein WO, Lohmann R, Radke C, Kling N et al (1999) Extended resections for hilar cholangiocarcinoma. Ann Surg 230(6):808–818, discussion 19
Ramos E (2013) Principles of surgical resection in hilar cholangiocarcinoma. World J Gastrointest Oncol 5(7):139–146
Neuhaus P, Thelen A, Jonas S, Puhl G, Denecke T, Veltzke-Schlieker W et al (2012) Oncological superiority of hilar en bloc resection for the treatment of hilar cholangiocarcinoma. Ann Surg Oncol 19(5):1602–1608
Shimizu H, Sawada S, Kimura F, Yoshidome H, Ohtsuka M, Kato A et al (2009) Clinical significance of biliary vascular anatomy of the right liver for hilar cholangiocarcinoma applied to left hemihepatectomy. Ann Surg 249(3):435–439
Zervos EE, Osborne D, Goldin SB, Villadolid DV, Thometz DP, Durkin A et al (2005) Stage does not predict survival after resection of hilar cholangiocarcinomas promoting an aggressive operative approach. Am J Surg 190(5):810–815
de Jong MC, Hong SM, Augustine MM, Goggins MG, Wolfgang CL, Hirose K et al (2011) Hilar cholangiocarcinoma: tumor depth as a predictor of outcome. Arch Surg 146(6):697–703
Valle JW, Wasan H, Johnson P, Jones E, Dixon L, Swindell R et al (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study—the UK ABC-01 Study. Br J Cancer 101(4):621–627
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N et al (2011) Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 18(3):651–658
Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H et al (2009) Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg 13(8):1470–1479
Dumitrascu T, Chirita D, Ionescu M, Popescu I (2013) Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg 17(5):913–924
Sanz-Altamira PM, Ferrante K, Jenkins RL, Lewis WD, Huberman MS, Stuart KE (1998) A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82(12):2321–2325
Rao S, Cunningham D, Hawkins RE, Hill ME, Smith D, Daniel F et al (2005) Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 92(9):1650–1654
Andersen JB, Thorgeirsson SS (2014) A perspective on molecular therapy in cholangiocarcinoma: present status and future directions. Hepatic Oncol 1(1):143–157
Ross JS, Wang K, Gay L, Al-Rohil R, Rand JV, Jones DM et al (2014) New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing. Oncologist 19(3):235–242
Tada S, Fujikawa T, Tanaka A, Abe T, Yoshimoto Y, Maekawa H et al (2012) A case of unresectable hilar cholangiocarcinoma successfully treated by gemcitabine and S-1 combination chemotherapy. Gan to Kagaku Ryoho Cancer Chemother 39(8):1279–1282
Grendar J, Grendarova P, Sinha R, Dixon E (2014) Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB 16(4):297–303
McMasters KM, Tuttle TM, Leach SD, Rich T, Cleary KR, Evans DB et al (1997) Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 174(6):605–608, discussion 8–9
Nelson JW, Ghafoori AP, Willett CG, Tyler DS, Pappas TN, Clary BM et al (2009) Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 73(1):148–153
Gerhards MF, Gonzalez DG, ten Hoopen-Neumann H, van Gulik TM, de Wit LT, Gouma DJ (2000) Prevention of implantation metastases after resection of proximal bile duct tumours with pre-operative low dose radiation therapy. Eur J Surg Oncol 26(5):480–485
Gerhards MF, van Gulik TM, Gonzalez Gonzalez D, Rauws EA, Gouma DJ (2003) Results of postoperative radiotherapy for resectable hilar cholangiocarcinoma. World J Surg 27(2):173–179
Todoroki T, Ohara K, Kawamoto T, Koike N, Yoshida S, Kashiwagi H et al (2000) Benefits of adjuvant radiotherapy after radical resection of locally advanced main hepatic duct carcinoma. Int J Radiat Oncol Biol Phys 46(3):581–587
Cheon YK, Lee TY, Lee SM, Yoon JY, Shim CS (2012) Longterm outcome of photodynamic therapy compared with biliary stenting alone in patients with advanced hilar cholangiocarcinoma. HPB 14(3):185–193
Witzigmann H, Berr F, Ringel U, Caca K, Uhlmann D, Schoppmeyer K et al (2006) Surgical and palliative management and outcome in 184 patients with hilar cholangiocarcinoma: palliative photodynamic therapy plus stenting is comparable to r1/r2 resection. Ann Surg 244(2):230–239
Dumoulin FL, Gerhardt T, Fuchs S, Scheurlen C, Neubrand M, Layer G et al (2003) Phase II study of photodynamic therapy and metal stent as palliative treatment for nonresectable hilar cholangiocarcinoma. Gastrointest Endosc 57(7):860–867
Quyn AJ, Ziyaie D, Polignano FM, Tait IS (2009) Photodynamic therapy is associated with an improvement in survival in patients with irresectable hilar cholangiocarcinoma. HPB 11(7):570–577
Wiedmann M, Caca K, Berr F, Schiefke I, Tannapfel A, Wittekind C et al (2003) Neoadjuvant photodynamic therapy as a new approach to treating hilar cholangiocarcinoma: a phase II pilot study. Cancer 97(11):2783–2790
Iwatsuki S, Todo S, Marsh JW, Madariaga JR, Lee RG, Dvorchik I et al (1998) Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 187(4):358–364
Meyer CG, Penn I, James L (2000) Liver transplantation for cholangiocarcinoma: results in 207 patients. Transplantation 69(8):1633–1637
Shimoda M, Farmer DG, Colquhoun SD, Rosove M, Ghobrial RM, Yersiz H et al (2001) Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 7(12):1023–1033
Darwish Murad S, Kim WR, Therneau T, Gores GJ, Rosen CB, Martenson JA et al (2012) Predictors of pretransplant dropout and posttransplant recurrence in patients with perihilar cholangiocarcinoma. Hepatology 56(3):972–981
Rosen CB, Heimbach JK, Gores GJ (2010) Liver transplantation for cholangiocarcinoma. Transpl Int 23(7):692–697
Hong JC, Jones CM, Duffy JP, Petrowsky H, Farmer DG, French S et al (2011) Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center. Arch Surg 146(6):683–689
Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK et al (2005) Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 242(3):451–458, discussion 8–61
Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM et al (2012) Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology 143(1):88–98, e3; quiz e14
Chauhan A, House MG, Pitt HA, Nakeeb A, Howard TJ, Zyromski NJ et al (2011) Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma. HPB 13(2):139–147
van Gulik TM, Ruys AT, Busch OR, Rauws EA, Gouma DJ (2011) Extent of liver resection for hilar cholangiocarcinoma (Klatskin tumor): how much is enough? Dig Surg 28(2):141–147
Shimizu H, Kimura F, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H et al (2010) Aggressive surgical resection for hilar cholangiocarcinoma of the left-side predominance: radicality and safety of left-sided hepatectomy. Ann Surg 251(2):281–286
Unno M, Katayose Y, Rikiyama T, Yoshida H, Yamamoto K, Morikawa T et al (2010) Major hepatectomy for perihilar cholangiocarcinoma. J Hepato-Biliary-Pancreat Sci 17(4):463–469
Lee SG, Song GW, Hwang S, Ha TY, Moon DB, Jung DH et al (2010) Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepato-Biliary-Pancreat Sci 17(4):476–489
El-Khoueiry AB, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD (2014) S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer 110:882–887
Rubovszky G, Lang I et al (2013) Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. Eur J Cancer 49(18):3806–3812
Jensen LH, Lindebjerg J, Ploen J et al (2012) Phase II marker-driven trial of panitumumab and chemotherapy in KRAS wild-type biliary tract cancer. Ann Oncol 23(9):2341–2346
Lubner SJ, Mahoney MR, Kolesar JL et al (2010) Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol 28:3491–3497
El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD (2012) SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 30(4):1646–1651
Valle JM et al (2014) ABC-04: A phase 1b trial of cisplatin, gemcitabine, and selumetinib in patients with advanced biliary tract cancer. J Clin Oncol 32:5s (abstr 4002)
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Weiss, M.J., Cosgrove, D., Herman, J.M. et al. Multimodal treatment strategies for advanced hilar cholangiocarcinoma. Langenbecks Arch Surg 399, 679–692 (2014). https://doi.org/10.1007/s00423-014-1219-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00423-014-1219-1